Tokyo, Japan – June 3, 2019 – LPIXEL Inc., a leader in image analysis and processing technology in life science and medical research, is pleased to announce the initiation of the artificial intelligence (AI) system development for cell evaluation with Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”). During the project, Astellas will access LPIXEL’s AI-instilled image analysis solution, IMACEL Lab, for the cell selection and management processes in conducting research on regenerative medicine and cell therapy.

AI for Cell Culture Quality Control on Regenerative Medicine and Cell Therapy
In recent years, much attention has been given to regenerative medicine and cell therapy, which is the field of science aimed at repairing damaged cells and tissues. The Astellas Institute for Regenerative Medicine (AIRM), a subsidiary of Astellas, is carrying out biopharmaceutical research and development including work on regenerative medicine and cell therapy.
In regenerative medicine and cell therapy, it is essential to maintain and select cells suitable for treatment. IMACEL Lab will assist in cell selection and maintenance.

About IMACEL Lab
IMACEL Lab aims to solve various needs in life science research and development, particularly in the medical, pharmaceutical and agricultural sectors by combining AI with the image analysis technologies* that the members of the company have been developing ever since its inception at the University of Tokyo laboratory in the year 2000. As with Astellas, LPIXEL will foster the development of new values through each of its partnerships.
* IMACEL: A cloud-based bioimage analysis platform for morphological analysis and image classification (2019) 

About LPIXEL
Founded in March 2014, LPIXEL is a University of Tokyo spin-off that hones its expertise in life science image analysis. LPIXEL unifies artificial intelligence and its image analysis technologies to develop and provide advanced software for researchers and professionals in the life science industry, including the medical, pharmaceutical and agricultural sectors. LPIXEL is currently working in collaboration with the University of Tokyo, the National Cancer Center Japan, and other research institutions to further the development of its AI-powered medical image diagnostic support technology, EIRL. For more information, please click here

Contact Details
Mariko Takahashi
LPIXEL Inc.
pr＠lpixel.net